Integra Lifesciences Holdings (IART) FCF Margin (2009 - 2026)

Integra Lifesciences Holdings has disclosed FCF Margin across 18 years of filings, most recently posting 2.51% for Q2 2026.

• In Q2 2026, FCF Margin rose 521.0% year-over-year to 2.51%; the TTM figure through Jun 2026 stood at 1.57% (up 387.0% YoY), while the FY2025 annual figure was 1.9%, down 345.0% from the prior year.
• FCF Margin came in at 2.51% for Q2 2026 at Integra Lifesciences Holdings, up from 1.29% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 17.81% in Q4 2022 to a low of 10.5% in Q1 2025.
• Average FCF Margin over 5 years is 4.13%, with a median of 3.3% recorded in 2023.
• Year-over-year, FCF Margin plunged 1178 bps in 2023 and surged 921 bps in 2026.
• Over 5 years, FCF Margin stood at 17.81% in 2022, then sank by 52 bps to 8.62% in 2023, then sank by 45 bps to 4.78% in 2024, then slumped by 126 bps to 1.24% in 2025, then surged by 302 bps to 2.51% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 2.51% in Q2 2026, 1.29% in Q1 2026, and 1.24% in Q4 2025.